DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Boosts Stock Holdings in Cencora, Inc. (NYSE:COR)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in Cencora, Inc. (NYSE:COR) by 28.6% during the 4th quarter, Holdings Channel reports. The firm owned 5,407 shares of the company’s stock after buying an additional 1,201 shares during the quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main’s holdings in Cencora were worth $1,215,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Hickory Asset Management Inc. bought a new stake in shares of Cencora in the fourth quarter worth about $572,000. Sylvest Advisors LLC bought a new stake in Cencora in the 4th quarter worth approximately $1,105,000. Vontobel Holding Ltd. increased its stake in Cencora by 46.9% in the 4th quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company’s stock worth $1,403,000 after acquiring an additional 1,995 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. raised its holdings in shares of Cencora by 71.1% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company’s stock worth $1,583,000 after acquiring an additional 2,928 shares in the last quarter. Finally, Milestone Asset Management LLC boosted its position in shares of Cencora by 430.2% during the 4th quarter. Milestone Asset Management LLC now owns 5,461 shares of the company’s stock valued at $1,227,000 after acquiring an additional 4,431 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In related news, EVP Silvana Battaglia sold 5,000 shares of the firm’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the sale, the executive vice president now owns 15,374 shares of the company’s stock, valued at $3,724,197.76. This trade represents a 24.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Robert P. Mauch sold 4,970 shares of Cencora stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the transaction, the chief executive officer now directly owns 51,070 shares in the company, valued at approximately $13,022,850. The trade was a 8.87% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 50,223 shares of company stock valued at $13,580,967. 10.80% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Citigroup boosted their price target on shares of Cencora from $330.00 to $355.00 and gave the stock a “buy” rating in a research report on Thursday. Wells Fargo & Company boosted their target price on Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research report on Friday, March 14th. StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. Bank of America boosted their target price on shares of Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a research note on Friday, April 11th. Finally, UBS Group raised their price target on shares of Cencora from $298.00 to $335.00 and gave the stock a “buy” rating in a research note on Tuesday, April 29th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $301.18.

Cencora Stock Performance

COR stock opened at $283.12 on Monday. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $309.35. The business has a 50-day moving average price of $276.48 and a 200 day moving average price of $253.57. The company has a market capitalization of $54.90 billion, a P/E ratio of 40.27, a PEG ratio of 1.31 and a beta of 0.60. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The business had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. During the same quarter in the previous year, the business posted $3.80 EPS. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. As a group, equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 2nd. Shareholders of record on Friday, May 16th will be issued a dividend of $0.55 per share. The ex-dividend date is Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a yield of 0.78%. Cencora’s dividend payout ratio is currently 25.52%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.